Cardiovascular comorbidities in spondyloarthritis
Clinical Rheumatology, vol.42, no.10, pp.2611-2620, 2023 (SCI-Expanded, Scopus)
- Publication Type: Article / Review
- Volume: 42 Issue: 10
- Publication Date: 2023
- Doi Number: 10.1007/s10067-022-06473-9
- Journal Name: Clinical Rheumatology
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
- Page Numbers: pp.2611-2620
- Keywords: Axial spondyloarthritis, Cardiovascular diseases, Cardiovascular risk factors, Comorbidity, Ischemic heart disease
- Ankara Yıldırım Beyazıt University Affiliated: Yes
Abstract
© 2022, The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).In recent years, many researchers have focused on the development of comorbidities associated with axial spondyloarthritis. Hypertension, smoking, dyslipidemia, diabetes mellitus, obesity, and the presence of inflammation, which is a well-known risk factor, increase cardiovascular comorbidities. Previous studies reported that HLA-B27 might be a genetic risk factor for various cardiac conditions. In the treatment and follow-up, raising the awareness of cardiovascular risk and guiding clinical practice and future research in rheumatic and musculoskeletal diseases should be aimed. There is consensus that cardiovascular risks should be evaluated periodically in these patients, particularly during the course of treatment. A decision regarding the selection and follow-up protocols of the drugs should be made considering all the risks and benefits in spondyloarthropathies. In this review, we discussed the recommendations and practices for the management of cardiovascular comorbidities in axial spondyloarthritis. Key Points• The risk of cardiovascular morbidity and mortality is increased in axial spondyloarthritis.• Higher disease activity increases cardiovascular risk factors.• Axial spondyloarthritis patients should be carefully monitored for signs of cardiovascular events as this is necessary to ensure that patients are treated appropriately and awareness should be raised in all patients.• Reducing the activity of the underlying disease with an appropriate and early treatment will also reduce the risk of cardiovascular events.